Ekso Bionics(EKSO)

Focus: Ekso Bionics is a public medical device company specializing in wearable exoskeleton technology for spinal cord injury rehabilitation and mobility restoration. The company operates at modest scale with $18M in annual revenue and a focus on robotic-assisted therapy applications.

Profile data last refreshed 3h ago · AI intelligence enriched Yesterday

Funding Stage

PUBLIC

Open Jobs

About Ekso Bionics

AI assessmentNot Hiring

No open roles listed right now. Follow Ekso Bionics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$18M

Pipeline & Clinical Trials

Ekso GT Rehabilitation Therapy

Injuries, Spinal Cord

N/A

Clinical Trials (1)

NCT02943915The WISE Trial - Walking Improvement for SCI With Exoskeleton

N/A

Help build intelligence for Ekso Bionics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneer in emerging exoskeleton market projected to reach $20.3B by 2035 at 22.4% CAGR, offering early-mover advantage in a high-growth segment.
Public company status (NASDAQ: EKSO) provides equity upside potential and institutional credibility compared to pre-revenue startups.
Focused pipeline addressing critical unmet need in spinal cord injury rehabilitation with multiple device iterations (Ekso GT, SmartAssist software, overground robotic platform).

Watch Out For

Severe cash burn: company posted $11.3M net loss on $18M revenue in FY 2025 with declining R&D spend ($4M vs $5M prior year), indicating financial distress.
Flat revenue trajectory ($18M in both FY 2025 and FY 2024) and minimal cash position ($4M) create sustainability risk; recent ticker change to ChronoScale raises questions about corporate stability.
Zero active job openings and no disclosed headcount suggest organizational contraction, limiting internal mobility and growth opportunities.

Generated by Claude from Ekso Bionics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Ekso

Spinal Cord Injury

N/A

Clinical Trials (1)

NCT02132702Performance Attributes and User Progression While Using Ekso

N/A

EksoGT with SmartAssist software

Debility Due to Disease

N/A

Clinical Trials (1)

NCT03355755Exoskeleton Treatment of Deconditioning Due to Limited Ambulation Caused by Illness or Injury

N/A

Ekso

Spinal Cord Injuries

N/A

Clinical Trials (1)

NCT02566850Investigational Study of the Ekso for High-Dosage Use by Individuals With SCI in a Non-Clinical Environment

N/A

Overground Robotic Exoskeleton

Spinal Cord Injury

N/A

Clinical Trials (1)

NCT07030322Health and Financial Impact on the Use of a Personal Exoskeleton in the Home and Community: a Case Study

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2005

Portfolio: 5 clinical trials

Publications: 2 in PubMed

SEC Filings: 2 available

Financials (FY2025)

Revenue

$18M2%

R&D Spend

$4M(22%)23%

Net Income

-$11M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(2)

Recent peer-reviewed publications with author affiliations at this company

Walking improvement in chronic incomplete spinal cord injury with exoskeleton robotic training (WISE): a randomized controlled trial.

Spinal cord

2022

PMID:35094007

Comparison of peak oxygen consumption response to aquatic and robotic therapy in individuals with chronic motor incomplete spinal cord injury: a randomized controlled trial.

Spinal cord

2019

PMID:30659286

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Ekso Bionics(EKSO)

About Ekso Bionics

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Ekso Bionics(10)

Open Jobs (0)

Financials (FY2025)

Hiring Trend

Research Publications(2)